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Abstract
Background: There are many different types of pediculicides available OTC in Australia. In this study we compare
the efficacy and safety of three topical pediculicides: a pediculicide containing melaleuca oil (tea tree oil) and
lavender oil (TTO/LO); a head lice “suffocation” product; and a product containing pyrethrins and piperonyl
butoxide (P/PB).
Method: This study was a randomised, assessor-blind, comparative, parallel study of 123 subjects with live head
lice. The head lice products were applied according to the manufacturer’s instructions (the TTO/LO product and
the “suffocation” product were applied three times at weekly intervals according to manufacturers instructions (on
Day 0, Day 7 and Day 14) and the P/PB product was applied twice according to manufacturers instructions (on
Day 0 and Day 7)). The presence or absence of live lice one day following the last treatment was determined.
Results: The percentage of subjects who were louse-free one day after the last treatment with the product
containing tea tree oil and lavender oil (41/42; 97.6%) and the head lice “suffocation” product (40/41, 97.6%) was
significantly higher compared to the percentage of subjects who were louse-free one day after the last treatment
with the product containing pyrethrins and piperonyl butoxide (10/40, 25.0%; adj. p < 0.0001).
Conclusion: The high efficacy of the TTO/LO product and the head lice “suffocation” product offers an alternative
to the pyrethrins-based product.
Trial Registration: The study was entered into the Australian/New Zealand Clinical Trial Registry,
ACTRN12610000179033.
Background
The incidence of head louse infestation is high in many
countries[1-3]. This may be explained, in part at least,
by the evolution in head lice of lower susceptibility
(resistance) to older pediculicides[4]. Two new types of
head lice products have found wide acceptance in many
countries: essential oil based products and products
designed to “suffocate” head lice. It is important to
assess and compare the lice kill rates and the safety of
these newer products with existing market leading pro-
ducts in well controlled and well designed clinical trials.
One essential oil based product containing 11.0%
eucalyptus oil was reported to have an efficacy of 82.5%
compared to a kill rate of 36.1% for a product contain-
ing pyrethrins and piperonyl butoxide using a study
design similar to that employed in this study[5]. In
another study a “suffocation” product containing 5%
benzyl alcohol was reported to kill all head lice in 92.2%
of subjects as measured one day after the second
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containing pyrethrins and piperonyl butoxide, studied by
ourselves previously, as a comparator[5], the efficacy
and safety of two new head lice products were studied
by us: NeutraLice Lotion® (containing melaleuca oil and
lavender oil) and NeutraLice Advance® (a “suffocation”
product).
Methods
Objectives and Interventions
To compare the efficacy and tolerance of three head lice
treatment products when used according to the manu-
facturers instructions:
1. Product containing melaleuca oil (tea tree oil) 10%
w/v and lavender oil 1% w/v (TTO/LO) (NeutraLice
Lotion® Key Pharmaceuticals Pty Ltd, Australia) pre-
sented as a clear oily solution
2. “suffocation” product containing benzyl alcohol,
mineral oil, polysorbate 80, sorbitan monooleate, Carbo-
pol 934, water and triethanolamine (NeutraLice
Advance® Key Pharmaceuticals Pty Ltd, Australia) pre-
sented as a white opaque lotion
3. Product containing pyrethrins 1.65 mg/g, and piper-
onyl butoxide 16.5 mg/g (P/PB) (Banlice Mousse® John-
son & Johnson Pacific Pty Ltd, Australia) presented as a
pressurised aerosol mousse
Methodology
This was an assessor blind, randomised, parallel group,
comparative study. The study population consisted of
primary school-aged children (aged 4 yrs to 12 yrs)
from three different schools in Queensland and their
siblings with live head lice (adults or nymphs) in their
hair or on their scalp. If parental written informed con-
sent was provided, the children were screened for the
presence of live head lice by visual inspection (see
Appendix 1 - Definitions) and by dry-combing (see
Appendix 1 - Definitions). Those subjects meeting the
entry criteria were randomised and treated with one of
the three head lice products. Subjects with a history of
allergies, presence of scalp disease and those who were
treated with a head lice product in the 4 weeks prior to
participation in this trial were excluded.
The TTO/LO and “suffocation” products were applied
three times, at weekly intervals, as per the manufac-
turer’s instructions (on day 0, day 7 and day 14). The P/
PB product was applied twice, as per the manufacturer’s
instructions (on day 0 and day 7). The louse-combing
procedure normally used in combination with these
three products was not done so we could compare the
efficacy of the components of each product without
confounding the efficacy measurements by physically
removing head lice by combing (which is a treatment in
itself).
The primary outcome measure was the louse free rate
(see Appendix 1 - Definitions) assessed one day after
the last treatment (at day 15 for TTO/LO and “suffoca-
tion” products and at day 8 after application of P/PB
product) and was determined by wet-combing (see
Appendix 1 - Definitions) for the Intention to Treat
population and the Per Protocol population. A second-
ary outcome measure, louse free rate at day 1, was
determined by dry-combing
Ethics
This trial was conducted in compliance with the World
Medical Association Declaration of Helsinki, the
requirements of the National Statement on Ethical
Conduct in Research Involving Humans, ICH E6 Gui-
dance for the Industry; Good Clinical Practice: Conso-
lidated Guidance, the National Privacy Principles and
relevant State/Territory laws. The trial activities were
approved by the Medical Research Ethics Committee
of the University of Queensland, project No.
2003000184 and all parents/guardians provided written
informed consent.
Randomisation
Eligible subjects were randomly assigned to receive one
of the three head lice treatments by a computer gener-
ated code using blocked randomisation (groups of six).
Blinding
This trial was assessor-blind. The person applying the
treatment could not avoid being aware of the product
being applied as the products are easily identifiable by
their physical attributes; however, assessor-blinding was
achieved by using different staff for applications on the
one hand and assessment and CRF data entry on the
other hand, and by physically separating these activities
at the investigational site. Subjects were prevented from
sighting the products being used. The parents of sub-
jects were also blinded to the treatment applications.
Analysts involved in data management were blinded to
the identification of each treatment group until the final
efficacy analysis for each treatment group was complete.
Treatment of siblings
If an enrolled subject had a primary-school aged sibling
(aged 4 years to 12 years), the sibling was also examined
for head lice and, if infested with live lice and available
for enrolment, this sibling was enrolled into the same
treatment arm as the subject. Those siblings not
enrolled, because they were unavailable for the trial for
any reason or had eggs only, were wet-combed-out at
days 0 and 7 for siblings of subjects receiving the P/PB
product or wet-combed-out (see Appendix 1 - Defini-
tions) at days 0, 7 and 14 for siblings of subjects receiv-
ing TTO/LO and “suffocation” products.
Treatment compliance
The Intent-to-Treat (ITT) population is defined as all
subjects receiving at least one treatment application.
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safety and efficacy.
Subjects who met all the protocol requirements are
termed the per-protocol (PP) population and this was
the secondary population for determination of efficacy.
Subjects are considered to be per protocol (PP) if they
satisfied the requirements listed in Appendix 2:
Dosage and dosage regimen
The doses, method of application and number of weekly
treatments were those recommended by the manufac-
turers. All three products were applied for 10 minutes.
After the TTO/LO product was applied the hair was
covered by a shower cap made of polyvinyl chloride to
retain the volatile components of the formulation. The
TTO/LO and “suffocation” products were then washed
out with water; the P/PB product was washed out with
a standard shampoo. The TTO/LO and “suffocation”
products were applied at weekly intervals on days 0, 7
and 14. The P/PB product was applied on days 0 and 7.
Criteria for evaluation of efficacy
The efficacy of each product is defined as the “louse-free
rate.” The louse free rate was assessed at day 1 (by dry-
combing), and at day 15 (by wet-combing) for those
subjects treated with TTO/LO or “suffocation” products
OR at day 8 (by wet-combing) for those subjects treated
with the P/PB product. In the case of the day 1 exami-
nation, dry-combing was used and combing was stopped
immediately if live lice were observed. A blinded asses-
sor conducted the hair and scalp examinations.
Often, visual inspection was sufficient to determine if
live lice are present especially in cases of severe infesta-
tion. In such cases, dry/wet-combing was not necessary
to confirm the presence of live lice. However, visual
inspection alone was insufficient to declare a subject as
“louse-free”.
Criteria for evaluation of safety (tolerance)
Subjects were interviewed on site regarding possible
adverse effects during and immediately following the
application procedure as well as just before the next
scheduled application by site staff. The incidence and
severity of adverse events was compared between treat-
ment groups. The ITT population was analysed for
safety.
Statistical and data management methods
Determination of sample size and data analysis Pre-
v i o u se f f i c a c ys t u d i e si n v o l v i n gt h eP / P Bp r o d u c t
reported a cure rate of 36.1%[4]. Assuming the efficacy
of the TTO/LO and “suffocation” products to be
approximately 70% in the ITT population, it was esti-
mated that 40 subjects in each group (assuming cluster-
ing, i.e. siblings will receive the same treatment as the
first subject enrolled in the family) were required to test
the hypothesis of superiority of the TTO/LO and “suffo-
cation” products with a two-sided test using alpha at or
less than 0.025 to allow for two pair-wise comparisons
with 75% power. For the unadjusted analysis the chi-
square test was used. For adjusted analysis the General-
ized Estimating Equations methodology was used to fit
the logistic regression model to account for the cluster-
ing within families.
Results
Efficacy
Subjects were enrolled between April and June 2009.
The disposition of subjects is shown in Figure 1. 505
subjects were screened, 132 were enrolled in the study
(43 were treated with TTO/LO product, 45 with “suf-
focation” product and 44 with the P/PB product). Of
these 132 subjects (ITT population), 123 subjects were
evaluable: 42 TTO/LO subjects; 41 “suffocation” pro-
duct subjects and 40 P/PB subjects; 9 subjects were
not assessed at a final visit. Of the 132 enrolled sub-
jects, 108 were deemed PP; 41 TTO/LO subjects, 37
“suffocation” product subjects and 30 P/PB subjects.
Reasons for a subject being deemed not PP were:
enrolled sibling not treated with the same product as
original subject; use of an alternative head lice treat-
ment during the trial; siblings not available for treat-
ment on same day as original subject; and subjects not
available for assessment. There were no subject with-
drawals. The day after the last treatment was day 15
for the TTO/LO and “suffocation” products and day 8
for the P/PB product.
With regard to the primary efficacy endpoint for the
ITT population (123 subjects in total who were assessed
after the final treatment) (Table 1), subjects in the
TTO/LO product group were more likely to be louse-
free on the day after the last treatment than subjects in
the P/PB product group (41 out of 42 subjects, 97.6%
vs. 10 out of 40 subjects, 25.0%; adj. p < 0.0001). In
addition, subjects in the “suffocation” product group
were more likely to be louse-free than subjects in the
P/PB product group (40 out of 41 subjects, 97.6% vs. 10
out of 40 subjects, 25.0%; adj. p < 0.0001). An analysis
in which the nine subjects who were not assessed after
the final treatment, when treated as if they were non-
responders, yielded similar results (Table 1).
With regard to the secondary endpoint of louse-free
rate for the PP population (108 subjects in total) (Table
2) one day following final treatment, subjects in the PP
population in the TTO/LO product group were more
l i k e l yt ob el o u s e - f r e eo nt h ed a ya f t e rt h ef i n a lt r e a t -
ment than subjects in the P/PB product group (40 out
of 41 subjects, 97.6% vs. 10 out of 30 subjects, 33.3%;
unadj. p < 0.0001). Similarly, subjects in the PP popula-
tion in the “suffocation” product group were more likely
to be louse-free on the day after the final treatment
than subjects in the P/PB product group (37 out of
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unadj. p < 0.0001).
With regard to the louse-free rates on day 1 (one day
after the first application for all treatments, secondary
endpoint), subjects in the ITT population in the TTO/
LO product group were more likely to be louse-free on
day 1 than subjects in the P/PB product group (90.3%
vs. 43.3%; adj. p = 0.001). Similarly, subjects in the ITT
population in the “suffocation” product group were
m o r el i k e l yt ob el o u s e - f r e eo nd a y1t h a ns u b j e c t si n
the P/PB product group (69.4% vs. 43.3%; adj. p =
0.0329). For this population on day 1, the difference in
louse-free rates for TTO/LO and “suffocation” products
was not statistically significant (p = 0.1009). Subjects in
the PP population in the TTO/LO product group were
more likely to be louse-free on day 1 compared to sub-
jects in the P/PB product group (90.0% vs. 57.1%; adj.
p = 0.0196). For the PP population on day 1, 72.4% of
the subjects in the “suffocation” product group were
louse-free, whereas 57.1% of the subjects in the P/PB
product group were louse-free; this difference was not
statistically significant (adj. p = 0.2986).
Families Enrolled 
N=73 
Safety Population 
N=132 
ITT Population 
N=132 
Per Protocol Population 
N=108 
Children Enrolled 
N=132 
Tea Tree/ 
Lavender 
Oil product
N=43 
Suffocation 
product 
N=45 
Pyrethrins/ 
Piperonyl 
butoxide 
product 
N=44 
 Tea Tree/ 
Lavender 
Oil product
N=43 
Suffocation 
product 
N=45 
Pyrethrins/ 
Piperonyl 
butoxide 
product 
N=44 
Tea Tree/ 
Lavender 
Oil product
N=41 
Suffocation 
product 
N=37 
Pyrethrins/ 
Piperonyl 
butoxide 
product 
N=30
505 subjects 
screened 
Tea Tree/ 
Lavender 
Oil product 
Evaluable 
at Day 15 
N=42  
Suffocation 
product 
Evaluable 
at Day 15 
N=41 
Pyrethrins/ 
Piperonyl 
butoxide 
product 
Evaluable at 
Day 8 
N=40
Figure 1 Disposition of subjects.
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ders of the effect of treatment on outcome since they
were not associated with the outcome. Using a multiple
logistic regression model adjusting for gender, hair
length, hair type, school attended and accounting for
clustering, there was still a statistically significant higher
louse-free rate at the day after the final treatment
among children treated with the TTO/LO product (p-
value = < 0.0001) and among children treated with the
“suffocation” product (p-value = < 0.0001) than among
children treated with the P/PB product.
Safety (tolerance)
Of the 132 subjects enrolled, 36 adverse events were
reported; 29 in relation to TTO/LO treatment; 3 in rela-
tion to “suffocation” product; and, 4 were related to P/
PB product treatment. All adverse events reported were
considered by the investigator to be related to study
treatment. No adverse reaction was considered to be
serious by definition. Some subjects reported more than
one adverse event - 20 TTO/LO product-subjects
(46.5%), 3 “suffocation” product-subjects (6.7%) and 4 P/
PB product-subjects (9.1%) reported at least one adverse
event.
The adverse events for the TTO/LO, “suffocation” and
P/PB products were rated as mild in severity with the
exception of 3 adverse events in relation to the TTO/
LO product which were rated as moderate in intensity.
These 3 adverse events occurred in 3 subjects and were
described as stinging of the eyes following product con-
tact with the eyes; stinging of the neck; and, erythema
o ft h es k i n .I no n ec a s ef o l lowing product-contact
(TTO/LO) with the eyes, the application was washed
out prior to the 10 minute contact time. In all other
Table 1 Louse-Free Rate the Day After Final Treatment (ITT Population)
P-value
Number Louse-
free
Louse-free
Percentage
Unadjusted Adjusted
Louse-free rate:
Tea Tree/Lavender Oil product versus
Pyrethrins/piperonyl butoxide
product
Tea Tree/Lavender Oil product 41 out of 42
(41 out of 43)
97.62%
(95.35%)
< 0.0001 < 0.0001
Pyrethrins/piperonyl butoxide
product
10 out of 40
(10 out of 44)
25.0%
(22.73%)
Louse-free rate:
Suffocation product
versus
Pyrethrins/piperonyl butoxide
product
Suffocation product 40 out of 41
(40 out of 45)
97.56%
(88.89%)
< 0.0001 < 0.0001
Pyrethrins/piperonyl butoxide
product
10 out of 40
(10 out of 44)
25.0%
(22.73%)
Subjects in the ITT population for whom there was no information regarding whether or not they had lice on the day after the last treatment (9 subjects) were
excluded from the first analysis of 123 subjects. When these 9 subjects were included in the analysis and counted as failures (132 subjects), the results are shown
in brackets.
Table 2 Louse-free Rate the Day After Final Treatment (PP population)
P-value
Number Louse-
free
Louse-free
Percentage
Unadjusted Adjusted*
Louse-free rate:
Tea Tree/Lavender Oil product
versus
Pyrethrins/piperonyl butoxide
product
Tea Tree/Lavender Oil product 40 out of 41 97.56 < 0.0001 *
Pyrethrins/piperonyl butoxide
product
10 out of 30 33.33
Louse-free rate:
Suffocation product
versus
Pyrethrins/piperonyl butoxide
product
Suffocation product 37 out of 37 100 < 0.0001 *
Pyrethrins/piperonyl butoxide
product
10 out of 30 33.33
*The adjusted p-values could not be calculated because the generalized Hessian matrix was not positive definitive (the off-diagonal elements are too few)
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was taken or required.
The most commonly reported adverse events in rela-
tion to the TTO/LO product were stinging (13 subjects,
30.2%), flaky scalp/dry scalp (8 subjects, 18.6%) and
erythema (4 subjects, 9.3%). In the case of the “suffoca-
tion” product 3 subjects (6.7%) reported flaky scalp/dry
scalp. In the case of the P/PB product, 3 subjects (6.8%)
reported flaky scalp/dry scalp and 1 subject (2.3%)
reported erythema.
The reported stinging or burning sensation associated
with the TTO/LO product (which has been reported
before with other essential oil based head louse pro-
ducts[5]) lasted from 3 minutes to 141 minutes and
erythema was reported to last from 5 minutes to 185
minutes in various subjects. Only one case of erythema
was reported with the P/PB product and its duration
was not recorded. Flaky scalp/dry scalp, when it
occurred in relation to the TTO/LO, “suffocation” or P/
PB products appeared to last for at least one day.
Discussion
The efficacy of the P/PB product in this study was simi-
lar to that reported for the same product in a previous
and similarly designed study of ours (25% as compared
to 36.1%, respectively)[5]. The efficacy of the TTO/LO
product (97.6%), however, exceeded the efficacy of
another essential oil product studied by us in a similarly
designed study (Moov Head Lice Solution®, 82.5%)[5].
The efficacy of the “suffocation” product we tested was
97.6% compared to 92.2% for another “suffocation” pro-
duct, which also contains 5% benzyl alcohol[6]. The
mechanism of action of essential oils in the treatment of
head lice is unknown but “suffocation” products are
thought to act by blocking the “breathing” spiracles of
lice. It has been postulated that benzyl alcohol may con-
tribute to the efficacy of suffocating products by “stun-
ning” the spiracles open and allowing the product to
block the respiratory apparatus.
It is likely, that the use of a shower cap to trap volatile
components of essential oils such as melaleuca oil and
eucalyptus oil contributes to the higher efficacy of these
products compared to the same products applied with-
out a shower cap. The use of a shower cap with essen-
tial oil products, however, also appears to be correlated
to a higher incidence of transient mild to moderate
stinging sensations, burning sensations, and erythema.
The sensitivity of the skin of children varies. The “suffo-
cation” product, which is highly efficacious yet caused
little skin irritation in the present study, would be a
good choice for children with inherently sensitive skin.
Wet combing is a very accurate method to diagnose
active head lice infestation[7]. In contrast to previous
studies by us, we determined efficacy one day after the
last treatment rather than seven days after the last treat-
ment, to reduce re-infestation, which, of course, con-
founds the assessment of efficacy[8]. In order to
determine and compare the safety and efficacy of the
products as they are used by parents and children, the
products were applied strictly in accordance with the
manufacturer’s instructions. In the case of the P/PB pro-
duct there were two applications, one week apart. In the
case of the TTO/LO and “suffocation” products there
were three applications one week apart. While some
might criticise our study design, this study design
allowed us to assess the efficacy of these products
according to the way the products will be used by par-
ents and children; and thus is highly desirable in our
opinion. It is yet to be determined if head lice will read-
ily develop resistance to essential oil products, which
contain a large number of different active ingredients,
and “suffocation” products, which do not act on the
nervous system of the louse.
Conclusions
The TTO/LO product and head lice “suffocation” pro-
duct were both > 97% effective and were almost four
times as effective as the P/PB product that we compared
them with, when used according to manufacturer
instructions. These results support the view that this
new “suffocation” product is as effective in controlling
head lice as an essential oil product applied with a
shower cap.
Appendix 1: Definitions
￿ louse-free rate
The proportion of subjects on whom no live head lice
(adults or nymphs) were found when combed by a spe-
cified method at a specified time point.
￿ visual inspection
Visual inspection involves a brief examination of the
hair assisted by parting of the hair in spots to determine
whether live lice are present. It may be used in conjunc-
tion with dry-combing to determine active infestation
with live lice.
￿ dry-combing
Combing from scalp to the hair tips using a head lice
comb and not using water or conditioner to assist
combing. Every part of the hair should be combed with
a metal-toothed lice comb up to 6 times. The hair may
be de-tangled with a wide-gap comb before dry-
combing.
￿ wet-combing
Standard commercial conditioner is applied liberally to
the hair, and the hair detangled with a regular wide-
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toothed lice comb to remove live lice. Every part of the
hair is combed 6 times, scalp to hair tips. During comb-
ing, the comb is wiped onto a white tissue and the wip-
ings are examined for lice. After combing, the
conditioner is rinsed or towelled from the hair as
desired by the subject. Wet-combing is a powerful
detection technique to determine the final infestation
status of a subject at the end of an efficacy trial, as the
conditioner traps the lice making it highly unlikely that
any lice in the hair will avoid detection. Thus, the likeli-
hood that a subject will be incorrectly categorised as
louse free when in fact a low grade infestation still exists
is substantially reduced[7].
The wet-combing method results in the smothering of
lice in conditioner and the removal of head lice from
the scalp, thus wet-combing has an irreversible effect on
a subject’s infestation status. Wet-combing was only
used at the completion of the head lice trial.
￿ wet-combed-out
“Wet-combed-out” is a therapeutic procedure which
uses the wet-combining technique (above) to ensure the
hair is louse free: wet-combing is continued until no live
lice are found in six continuous passes of the comb.
This is repeated for every section of the hair.
Appendix 2: Criteria for assessing a subject as Per
Protocol
￿ They comply with all inclusion and exclusion protocol
requirements
￿ Have a signed informed consent authorisation
￿ Treatment was administered on day 0, 7 and 14 for
Tea Tree/Lavender Oil or suffocation products or treat-
ment was administered on days 0 and 7 for the Pyre-
thrins/piperonyl butoxide product
￿ Are evaluated using the wet-combing procedure at
one day after the final application (day 15 in the case of
Tea Tree/Lavender Oil or suffocation products or day 8
in the case of Pyrethrins/piperonyl butoxide product)
￿ The subject’s Case Report Form is sufficiently com-
plete to enable a valid assessment of efficacy and safety.
￿ Have not used any other head lice products during
the trial or in the 4 weeks preceding the trial
￿ Have not used any other head lice products other
than those specified in the protocol during the trial
￿ Has not used a head lice comb during the trial
￿ Have not bleached or dyed their hair during the trial
￿ The subject’s siblings were assessed and treated, if
required, as per the section “Treatment of siblings”
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